Promising early trial combines targeted drug with radiation for rare sarcoma
NCT ID NCT02787642
First seen Feb 26, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This early-phase study tested the safety of adding the drug olaparib to standard radiation therapy for people with advanced soft-tissue sarcoma that could not be removed by surgery. 41 adults took part. The main goals were to find the highest safe dose of olaparib and to see how many patients had their tumor shrink or stay stable after 6 months. The results help guide future research on this combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud - IUCT
Toulouse, 31052, France
-
Institut du Cancer de Montpellier
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.